ReviewLeukemia2008
The history of myeloproliferative disorders: before and after Dameshek.
Review in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.Annals of hematology · 2026Pooled it
- Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future.American journal of hematology · 2025Review
- History of Leukemia, Revisited.Current oncology reports · 2025Review
- Review
- Review
- Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update.Biomolecules · 2021Review
- Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.Oncology letters · 2021Article
- Retrospective analysis of the clinical features of 172 patients withMolecular cytogenetics · 2020Article
- Cytokines frequently implicated in myeloproliferative neoplasms.Cytokine: X · 2019Review
- From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Haematologica · 2017Review
- New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Review
- Quantitative analyses of myelofibrosis by determining hydroxyproline.Stem cell investigation · 2015Article
- Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Journal of hematology & oncology · 2014Article
- Article
- Molecular classification of myeloproliferative neoplasms-pros and cons.Current hematologic malignancy reports · 2013Review
- One thousand patients with primary myelofibrosis: the mayo clinic experience.Mayo Clinic proceedings · 2012Article
- Primary myelofibrosis and the "bad seeds in bad soil" concept.Fibrogenesis & tissue repair · 2012Article
- Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.The Journal of molecular diagnostics : JMD · 2011Article
- Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.Blood cancer journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1951, William Dameshek described the concept of 'myeloproliferative disorders (MPDs)' by grouping together chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and erythroleukemia; he reasoned that a self-perpetuating trilineage myeloproliferation underlined their pathogenesis. Pre-Dameshek luminaries who laid the foundation for this unifying concept include Bennett, Virchow, Heuck, Vaquez, Osler, Di Guglielmo and Epstein. In 1960, Nowell and Hungerford discovered the Philadelphia (Ph) chromosome in CML. In 1967, Fialkow and colleagues used X-linked polymorphisms to establish CML as a clonal stem cell disease. Also in 1967, the PV Study Group was summoned by Louis Wasserman to study the natural history of PV and conduct large-scale clinical trials. In 1972, Janet Rowley deciphered the Ph chromosome as a reciprocal translocation between chromosomes 9 and 22, thus paving the way for its subsequent characterization as an oncogenic BCR-ABL mutation. In 1996, Brian Druker discovered imatinib-a small molecule ABL inhibitor with exceptional therapeutic activity in CML. In 2005, a gain-of-function JAK2 mutation (JAK2V617F) was described in BCR-ABL-negative MPDs, raising the prospect of a CML-like treatment strategy in PV, ET and PMF. The current review considers these and other landmark events in the history of MPDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.